Vasomune Therapeutics Inc
February 26, 2024
Respiratory
Vasomune Therapeutics Inc., is a clinical stage biopharma, with an asset in mid-phase 2a. AV-001, is a Tie-2 agonist that corrects vascular endothelial dysfunction and shows strong activity against life-threatening diseases such as pulmonary edema and Acute Respiratory Distress Syndrome. Vasomune has received more than $12M in non-dilutive funding from the US Department of Defense and Canadian National Research Council, as well as more than $15M in support from our co-development partner, AnGes Inc. We are raising $15M USD to support our clinical development program in ARDS, specifically phase 2b and manufacturing
)
){kind=logo}
)
){kind=logo}
){kind=logo}